Advisors Preferred LLC Purchases 33,344 Shares of Exelixis, Inc. $EXEL

Advisors Preferred LLC grew its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 165.1% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 53,538 shares of the biotechnology company’s stock after purchasing an additional 33,344 shares during the quarter. Advisors Preferred LLC’s holdings in Exelixis were worth $2,206,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. TriaGen Wealth Management LLC purchased a new stake in Exelixis in the third quarter worth $2,024,000. BridgePort Financial Solutions LLC purchased a new stake in shares of Exelixis during the third quarter valued at $517,000. Candriam S.C.A. grew its holdings in shares of Exelixis by 18.4% in the third quarter. Candriam S.C.A. now owns 696,104 shares of the biotechnology company’s stock worth $28,749,000 after purchasing an additional 108,367 shares during the last quarter. Allianz Asset Management GmbH increased its stake in Exelixis by 153.3% in the 3rd quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company’s stock worth $101,720,000 after buying an additional 1,490,520 shares during the period. Finally, Fox Run Management L.L.C. purchased a new position in Exelixis in the 2nd quarter worth about $321,000. Institutional investors own 85.27% of the company’s stock.

Insider Transactions at Exelixis

In other news, EVP Patrick J. Haley sold 67,814 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $43.52, for a total value of $2,951,265.28. Following the sale, the executive vice president directly owned 381,908 shares in the company, valued at approximately $16,620,636.16. This trade represents a 15.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bob Oliver sold 30,250 shares of the business’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $43.81, for a total value of $1,325,252.50. Following the transaction, the director directly owned 21,120 shares of the company’s stock, valued at approximately $925,267.20. This represents a 58.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 285,058 shares of company stock valued at $12,460,245. 2.82% of the stock is owned by corporate insiders.

Exelixis Trading Down 1.2%

Shares of EXEL stock opened at $43.63 on Friday. The stock has a 50 day moving average of $43.88 and a 200 day moving average of $41.22. The stock has a market cap of $11.33 billion, a P/E ratio of 15.75, a P/E/G ratio of 0.98 and a beta of 0.42. Exelixis, Inc. has a twelve month low of $32.38 and a twelve month high of $49.62.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.20. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The business had revenue of $598.66 million for the quarter, compared to analyst estimates of $609.17 million. During the same period in the prior year, the company posted $0.55 EPS. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. On average, research analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on EXEL shares. Wolfe Research began coverage on Exelixis in a research report on Tuesday, November 18th. They set a “peer perform” rating on the stock. Guggenheim lowered shares of Exelixis from a “buy” rating to a “neutral” rating in a report on Monday, November 3rd. HC Wainwright increased their price objective on shares of Exelixis from $52.00 to $54.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Citigroup lowered shares of Exelixis from a “market outperform” rating to an “underperform” rating in a report on Monday, January 5th. Finally, Oppenheimer restated a “market perform” rating and set a $36.00 target price on shares of Exelixis in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $47.11.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.